造血干细胞嵌合体诱导移植免疫耐受

造血干细胞混合嵌合体是指两个不同基因型个体的骨髓造血干细胞共存的一种状态。在同种异体或异种移植的动物模型中,造血干细胞混合嵌合体巳成功地诱导出针对供者特异性的免疫耐受。现已证实造血干细胞具有否决活性,来自造血干细胞的否决细胞在诱导移植特异性免疫耐受中可能起重要作用。     

胚胎干细胞向造血系统的分化

胚胎干细胞是指从囊胚期的内细胞团中分离出来的尚未分化的胚胎细胞,可分化形成各种组织类型。在合适的条件下,胚胎干细胞可发育成造血干细胞及各类成熟血细胞,为造血干细胞移植及血细胞输注开辟了新的来源,同时也为造血发生及造血调控研究提供了有效可靠的模型。本文将综述ES细胞向造血系统分化的诱导条件、调控机制及应用前景。     

锂对造血干细胞和神经干细胞作用影响的研究进展

锂在现代精神病学中使用超过65年,其构成了双相情感障碍（BD）长期治疗的基础。锂的许多生物学特性已经被证实,包括抗病毒、血液系统和神经系统保护作用。本文系统综述了锂对造血干细胞（HSCs）、神经干细胞（NSCs）以及诱导多能干细胞（iPSCs）作用影响的研究进展及其目前已证实的分子机制。自20世纪70年代以来,锂对保持HSCs和生长因子高水平的作用已被报道。锂可以改善HSCs的归巢能力、形成菌落的能力和自我更新的能力。关于锂对神经发生影响的研究表明,锂可促进海马齿状回的干细胞增殖,并导致施旺氏细胞有丝分裂活性增强。锂被证实与神经保护和神经营养作用相关,具体作用反映在锂可改善突触的可塑性,促进细胞存活,抑制细胞凋亡等。在临床研究中发现,锂离子的治疗可增加大脑灰质的成分,尤其作用在额叶、海马和杏仁核等位置。锂对干细胞的作用涉及多条介质和信号通路,其中最重要的介质和信号通路被认为是糖原合成酶激酶-3（GSK-3）和Wnt/β-catenin通路,另外包括调节cAMP、蛋白激酶B、磷脂酰肌醇3-激酶（pi3k）和肌醇单磷酸酶（IMP）水平的信号通路等也与锂作用有紧密的联系。锂在现阶段被利用于治疗BD和降低痴呆症患病风险的临床实验中,并对神经退行性疾病发挥有益作用。除此之外,为了研究的发病机制和锂离子在其中的作用机制,从BD患者中获得的iPSCs也被广泛应用。     

造血干细胞移植与捐献

造血干细胞移植技术在临床上的应用越来越广泛,是目前白血病等难治性疾病的重要治疗方法之一,给广大患者带来了福音,但目前造血干细胞来源不足制约了其在临床上的广泛应用。介绍了造血干细胞移植与捐献的相关知识,包括造血干细胞移植的种类、临床应用、采集的过程、捐献的流程及捐献对供体的安全性等,旨在提高对造血干细胞捐献的认识。     

干细胞释疑

科学家对干细胞医学前景的描述,让患者大受鼓舞,点燃了重生的希望。但伦理道德的争议和研究进展的曲折,却使更多人迷惑——一个小小的细胞真能引发一场全人类的医疗革命?交织着宗教、政治、科学、文化等各种声音的大争论焦点在哪里?从实验室到临床,干细胞还要走多久?     

造血干细胞的研究进展

干细胞研究是一门新兴的学科。经过50多年的努力,造血干细胞的研究已经成为当今生物医学领域中发展最快的领域。介绍了造血干细胞的来源、分离纯化和检测方法以及“可塑性”等方面的研究情况,并详细说明了一些主要的造血干细胞表面标志以及造血干细胞在干细胞移植、细胞治疗和基因治疗等方面的临床应用和前景。     

胚胎干细胞体外分化为造血干细胞

造血干细胞移植已成为治疗白血病、再生障碍性贫血、重症免疫缺陷征、地中海贫血、急性放射病、某些恶性实体瘤和淋巴瘤等造血及免疫系统功能障碍性疾病的成熟技术和重要手段,另外这一技术还被尝试用于治疗艾滋病,已取得积极的效果。但是由于移植需要配型相同的供体,并且过程复杂,使得造血干细胞移植因缺少配型相同的供体来源以及费用昂贵而不能被广泛应用。胚胎干细胞是一种能够在体外保持未分化状态并且能进行无限增殖的细胞,在适合条件下能够分化为体内各种类型的细胞,研究胚胎干细胞分化为造血干细胞,不仅可作为研究动物的早期造血发生的模型,而且可以增加造血干细胞的来源,还可以通过基因剔除、治疗性克隆等方法来解决移植排斥的问题,从而为造血干细胞移植的发展扫除了障碍,因此有着重要的研究价值和应用前景。现对胚胎干细胞体外分化为造血干细胞的诱导方法,诱导过程中的调控机制,并对胚胎干细胞分化为造血干细胞的存在问题和发展前景进行讨论。     

小鼠造血干细胞增殖与分化性能的研究

本文选择Ｙ染色体特异的性别决定基因作为新的细胞遗传标志,采用ＰＣＲ技术研究了小鼠造血干细胞的增殖与分化性能。将雄鼠骨髓细胞输注给经致死剂量射线照射的雌性受体小鼠、ＰＣＲ测试结果表明,所有ＣＦＵ－Ｓ均为供体起源。供体来源的ＣＦＵ－Ｓ在其输入体内后,可通过增殖,分化形成各系造血细胞,但ＣＦＵ－Ｓ中的纤维母细胞和ＣＦＵ－Ｓ重建造血后受体小鼠骨髓中的纤维母细胞均为受体起源。由此可见,小鼠骨髓中的ＣＦＣ－Ｓ     

胚胎干细胞向造血细胞分化研究

胚胎干（embryonic stem,ES）细胞是来源于囊胚的内细胞团（inner cell mass,ICM）,具有发育的全能性或多能性,能嵌合到早期胚胎,在体内可以参与各种组织发育甚至包括生殖细胞;在体外分化培养条件下,可以顺序分化出各种组织细胞,与体内完整胚胎发育过程相符合,而且可以通过调节ES细胞某些基因的表达而调节其分化。因此,ES细胞是研究哺乳动物早期胚胎发育、细胞分化及其关键基因鉴定的理想模型。另外,胚胎生殖脊（embryonic germ,EG）细胞系也具有同样的生物学特性,它是由早期胚胎的原始生殖脊（primordial germ,PG）细胞建株而来。最近研究显示：ES细胞在体外不但可以分化为所有造血细胞系,而且还可以分化为具有长期增殖能力的造血干细胞。作者就胚胎干细胞向造血细胞和造血干细胞分化及其诱导因子和调控基因的表达作一综述。     

Exo-1基因对端粒酶缺陷小鼠造血干细胞植入效率的影响

目的利用不同的造血干细胞移植方式,探讨Exo-1基因缺失对端粒酶基因敲除小鼠的造血干细胞植入效率的影响。方法以CD45.1小鼠的骨髓细胞或骨髓造血干细胞为供体,以端粒酶基因敲除小鼠或Exo-1基因和端粒酶基因双敲除小鼠为受体,在给予不同剂量X线照射或不照射的情况下,重复进行静脉注射全骨髓细胞或分选的骨髓造血干细胞(c-kit+、Sca-1+、lineage-,KSL),于移植后1个月取外周血,流式分析嵌合率。结果未经X线照射及1 Gy、2 Gy照射情况下,端粒酶基因缺陷受体小鼠的外周血中供体来源的细胞嵌合率较低;6 Gy照射后,供体来源的外周血细胞嵌合率仍低于50%,而且端粒酶基因缺陷受体小鼠在移植后1个月内死亡较多;3 Gy照射可形成较高嵌合率,Exo-1基因缺失对端粒酶缺陷小鼠的造血干细胞植入效率的影响不显著。结论以端粒酶缺陷小鼠作为衰老模型研究造血干细胞植入效率时,3 Gy X线照射能够有效地形成较高的外周血供体细胞的嵌合率,但是Exo-1基因没有进一步提高造血干细胞在端粒酶敲除小鼠的植入效率。     

Niches of Hematopoietic Stem Cells in Bone Marrow

Molecular Biology - Hematopoietic stem cells (HSCs) exist in a close contact with their specific microenvironment, called a niche, which supports the HSC function and significantly influences the...     

N-Cadherin-Expressing Bone and Marrow Stromal Progenitor Cells Maintain Reserve Hematopoietic Stem Cells

1. Download high-res image (264KB)
2. Download full-size image

     

骨髓造血干细胞微环境

近来成体干细胞的研究进展为许多重大疾病的治疗带来了新的希望.造血干细胞 (hematopoietic stem cells, HSCs)是迄今认识到的最为典型的成体干细胞, 骨髓是干细胞研究的主要组织, 许多成体干细胞的概念及其基本特征源于对骨髓中造血干细胞的研究.近年来的重要进展之一是微环境对HSCs的调节功能, 干细胞微环境有准确的解剖学定位, 也是一个生理功能的基本单位, 整合介导机体对干细胞需求的反应信号, 从而调节干细胞的数量和命运.在病理条件下, 微环境仍然调节干细胞的功能, 因此对造血微环境的认识已成为干细胞研究的中心内容.现对骨髓造血干细胞微环境的组成、信号及修饰的研究进展进行综述, 为深入研究干细胞微环境的结构和功能提供背景资料.     

稳态及衰老情况下骨髓微环境对造血干细胞的调控作用

稳态下,骨髓微环境(bone marrow microenvironment)被证实能通过多种信号通路和细胞因子调控造血干细胞(hematopoietic stem cells,HSCs)的自我更新、增殖、分化和迁移能力以维持造血系统的稳定.在衰老过程中,HSCs功能受损会导致造血系统功能的退化以及年龄相关的免疫应答的...     

Homing of Hematopoietic Cells to the Bone Marrow

Homing is the phenomenon whereby transplanted hematopoietic cells are able to travel to and engraft or establish residence in the bone marrow. Various chemomkines and receptors are involved in the homing of hematopoietic stem cells. [1, 2]This paper outlines the classic homing protocol used in hematopoietic stem cell studies. In general this involves isolating the cell population whose homing needs to be investigated, staining this population with a dye of interest and injecting these cells into the blood stream of a recipient animal. The recipient animal is then sacrificed at a pre-determined time after injection and the bone marrow evaluated for the percentage or absolute number of cells which are positive for the dye of interest. In one of the most common experimental schemes, the homing efficiency of hematopoietic cells from two genetically distinct animals (a wild type animal and the corresponding knock-out) is compared. This article describes the hematopoietic cell homing protocol in the framework of such as experiment.     

Effects of Bone Marrow Mesenchymal Stem Cells on Hematopoietic Recovery and Acute Graft-Versus-Host Disease in Murine Allogeneic Umbilical Cord Blood Transplantation Model

To investigate the effect of bone marrow mesenchymal stem cells (MSC) on hematopoietic recovery and acute graft-versus-host disease (GVHD) in a murine allogeneic umbilical cord blood transplantation (allo-UCBT) model. MSCs were obtained from C57/BL mouse bone marrow. The MSC phenotypes were identified by flow cytometry (FCM), and their ability to differentiate into osteoblasts and adipocytes was tested. Once murine allo-UCBT and aGVHD models were established, mice were divided into five groups: (1) total body irradiation (TBI) group, each mouse receiving 0.3 ml sterile saline infusion after TBI and used as control; (2) UCB group, receiving 2 × 10⁶ umbilical cord blood mononuclear cells (UCB-MNC) after TBI; (3) UCB+MSC group, receiving 2 × 10⁶ UCB-MNC and 2 × 10⁷ MSC after TBI; (4) UCB+SC group, receiving 2 × 10⁶ UCB-MNC and 2 × 10⁶ spleen cells after TBI; and (5) UCB+SC+MSC group, receiving 2 × 10⁶ UCB-MNC, 2 × 10⁷ MSC and 2 × 10⁶ spleen cells after TBI. To evaluate the engraftment of HSC, the white blood cells, red blood cells, and platelets counts were tested at different time points after transplantation, and the ratio of chimerism was identified by FCM. The acute GVHD clinical scores, recipient mice survival, and the histopathological analyses were used to evaluate the effect of MSC on acute GVHD. MSCs were successfully obtained in vitro and FCM analysis showed that these cells are highly positive for CD90.2, CD44, and negative for CD34, CD45, and they are capable to differentiate into osteoblasts and adipocytes after being induced. Compared to UCB group, the UCB+MSC mice had shorter duration of myelosuppression and higher percentage of donor-derived cells which was up to 22.87 ± 4.3 % and the white blood cell (WBC), red blood cell (RBC), and platelet counts started to increase by day 6 after transplantation. Moreover, the average survival time for UCB+MSC mice was 25.0 ± 10.55 days, while for the UCB group it was 15.5 ± 12.50 days. The UCB+SC mice showed fatigue, loss of appetite, weight loss, arched back, and hair ruffling on day 13 post transplantation. Approximately 50 % of mice showed skin ulcers, had diarrhea and other manifestations of acute GVHD, and all mice were died within 20 days. Histopathological analysis confirmed grade II–IV GVHD manifestation. In addition to transient weight loss, some UCB+SC+MSC mice developed arched back, hair ruffling, diarrhea and other manifestations of acute GVHD. The clinical scores in UCB+SC+MSC mice with acute GVHD (grade I–II or without GVHD) were lower than UCB+SC group (P < 0.05). Bone marrow MSCs can promote hematopoietic recovery and decrease the incidence of acute GVHD in murine allo-UCBT model.     

异基因造血干细胞移植中的树突状细胞

树突状细胞(DC)是目前已知的启动免疫反应最强大的抗原呈递细胞(APC),也是惟一能激活初始T细胞的APC。近年来,DC在移植免疫中的作用已成为研究的焦点。简要综述了DC在异基因造血干细胞移植中的研究进展。     

Self-Renewing Human Bone Marrow Mesenspheres Promote Hematopoietic Stem Cell Expansion

1. Download : Download full-size image

     

Leukodystrophy and Bone Marrow Transplantation: Role of Mixed Hematopoietic Chimerism

Bone Marrow Transplantation (BMT) is currently the most physiologic treatment for some types of leukodystrophies. In enzyme deficiency states, replacement of defective genes with cells carrying normal copies of these genes offers a natural form of gene therapy. This review will cover the various disease states which may be treated using bone marrow transplantation as well as the obstacles and advantages offered by this treatment modality. The potential for mixed hematopoietic chimerism, with reference to the advantages and disadvantages of treating various leukodystrophies, is reviewed. Finally, certain approaches which would reduce the morbidity and mortality associated with conventional BMT are discussed. If these obstacles can be overcome, BMT may offer the hope of cure to a number, but certainly not all, leukodystrophies.     

Normal Hematopoietic Stem Cells within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level than Co-Existing Leukemic Stem Cells

Persistence of leukemic stem cells (LSC) after chemotherapy is thought to be responsible for relapse and prevents the curative treatment of acute myeloid leukemia (AML) patients. LSC and normal hematopoietic stem cells (HSC) share many characteristics and co-exist in the bone marrow of AML patients. For the development of successful LSC-targeted therapy, enabling eradication of LSC while sparing HSC, the identification of differences between LSC and HSC residing within the AML bone marrow is crucial. For identification of these LSC targets, as well as for AML LSC characterization, discrimination between LSC and HSC within the AML bone marrow is imperative. Here we show that normal CD34+CD38– HSC present in AML bone marrow, identified by their lack of aberrant immunophenotypic and molecular marker expression and low scatter properties, are a distinct sub-population of cells with high ALDH activity (ALDH^bright). The ALDH^bright compartment contains, besides normal HSC, more differentiated, normal CD34+CD38+ progenitors. Furthermore, we show that in CD34-negative AML, containing solely normal CD34+ cells, LSC are CD34– and ALDH^low. In CD34-positive AML, LSC are also ALDH^low but can be either CD34+ or CD34–. In conclusion, although malignant AML blasts have varying ALDH activity, a common feature of all AML cases is that LSC have lower ALDH activity than the CD34+CD38– HSC that co-exist with these LSC in the AML bone marrow. Our findings form the basis for combined functionally and immunophenotypically based identification and purification of LSC and HSC within the AML bone marrow, aiming at development of highly specific anti-LSC therapy.